The multifaceted world of angiogenesis control

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 11, 2010, Pages 1135-1138

  Guidolin, Diego ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Adrenomedullin; Angiogenesis; Antiangiogenic therapy; Cancer

Indexed keywords

ADRENOMEDULLIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; DRUG TARGETING; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ADRENOMEDULLIN; ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DESIGN; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ADRENOMEDULLIN; SIGNAL TRANSDUCTION;

EID: 77958072761     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.524048     Document Type: Review

References (17)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
2. Ribatti D, Vacca A, Dammacco F. The role of vascular phase in solid tumor growth: a historical review. Neoplasia 1999;1:293-302
3. Ribatti D, Nico B, Crivellato E, et al. The history of the angiogenic switch concept. Leukemia 2007;21:44-52
4. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863
5. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6:572-577
6. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9:639-651
7. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling in control of vascular function. Nat Rev 2006;7:359-371
8. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-684
9. Cook K, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222-243
10. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous regulators of angiogenesis. Pharmacol Rev 2007;59:185-205
11. Deville JL, Salas S, Figarella-Branger D. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets 2010;14:1059-1073
12. Poyner DR, Sexton PM, Marshall I, et al. International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adenomedullin, amylin and calcitonin receptors. Pharmacol Rev 2002;54:233-246
13. Ribatti D, Nico B, Spinazzi R, et al. The role of adrenomedullin in angiogenesis. Peptides 2005;26:1670-1675
14. Shindo T, Kurihara Y, Nishimatsu H, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001;104:1964-1971
15. Guidolin D, Albertin G, Spinazzi R, et al. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides 2008;29:2013-2023
16. Fernandez-Sauze S, Delfino C, Mabrouk K, et al. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004;108:797-804
17. Albertin G, Sorato E, Oselladore B, et al. Involvement of vascular endothelial growth factor signaling in CLR/ RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells. Int J Mol Med 2010;26:289-294